Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Citi
McKesson
Harvard Business School
Johnson and Johnson
Julphar
Accenture
Farmers Insurance
Federal Trade Commission

Generated: October 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,545,808

« Back to Dashboard

Title:Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran
Abstract: The subject invention relates to the compositions for radiolabeling Diethylenetriaminepentaacetic Acid (DTPA)-dextran with Technetium-99m and for stabilizing the DTPA-dextran Cold Kit. The composition contains Stannous Chloride ions to reduce .sup.99mTc-pertechnetate, Ascorbic Acid to reduce stannic ions to stannous ions to maintain a reducing environment, .alpha.,.alpha.-Trehalose to add bulk and to stabilize the lyophilized composition without interfering with the radiochemical yield, and Glycine to transchelate Technetium-99m under highly acidic conditions to facilitate radiolabeling DTPA-dextran with high radiochemical purity. In addition, the invention pertains to methods for making and using the compositions. The reconstitution of the lyophilized composition by .sup.99mTc-pertechnetate, resulting in radiolabeled .sup.99mTc-DTPA-dextran in a composition between pH 3 to 4. This invention contains a Diluent vial, which when used will shift the pH to a moderately acidic pH, which would provide less pain on injection and ease-of-use to clinical practitioners for adjusting its potency.
Inventor(s): Magneson; Gerald Ross (Needham, MA), Orahood; Richard Cushman (Delaware, OH)
Assignee: Navidea Biopharmaceuticals, Inc. (Dublin, OH)
Filing Date:May 01, 2012
Application Number:13/461,306
Claims:1. A method for stabilizing a DTPA-dextran cold kit for long-term storage, compromising the steps of: (a) adding an aqueous composition, compromising: (i) a sugar selected from the group of non-reducing disaccharides with a concentration up to 2% (w/v); (ii) a pH buffer selected from a group of pH buffers in concentration range of up to about 0.5 mg/mL; to a vessel containing about 90% of its target volume of degassed and deaerated water for injection; (b) adding a non-sulfhydryl anti-oxidant wherein the concentration is in the range of about 0.5 mg/mL; (c) adjusting the solution pH to a target pH of 3.2.+-.0.2 with 6 N hydrochloric acid, while maintaining an inert gas sparge; (d) adding a stannous salt wherein the concentration of the dihydrate form of the stannous salt is up to 75 micrograms/mL; (e) adding a DTPA-dextran with a concentration of up to 0.50 mg/mL; (f) adjusting the solution pH to a target pH of 3.2.+-.0.2 with 6 N hydrochloric acid, while maintaining an inert gas sparge; (g) adjusting the volume of the formulation to 100% of its target volume with degassed and deaerated water for injection; (h) filtering the aqueous composition through a 0.22 micron filter and filling the aqueous composition in to glass vials with 1.0 mL.+-.10%; (i) removing the majority of the water content of the product, decreasing the residual moisture to about less than 1% water content by lyophilization; (j) backfilling the lyophilized product with an inert gas to about 11.5 p.s.i. prior to stoppering the vials; (k) crimping the lyophilized product vials with aluminum seals; and (l) storing the crimped-sealed lyophilized product vials at either 2.degree. to 8.degree. C. or 25.degree..

2. The method of claim 1, wherein the non-reducing disaccharide is .alpha.,.alpha.-Trehalose Dihydrate.

3. The method of claim 1, wherein the pH buffer is Glycine.

4. The method of claim 1, wherein the non-sulfhydryl anti-oxidant is L(+)-Ascorbic Acid Sodium salt.

5. The method of claim 1, wherein the stannous salt is Stannous Chloride Dihydrate.

6. The method of claim 1, wherein the DTPA-dextran contains multiple DTPA groups conjugated to dextran in the molar ratio range of about 2:1 to 12:1.

7. The method of claim 1, wherein the DTPA-dextran contains dextran in the average molecular weight range of about 5,000 to 20,000 Daltons.

8. The method of claim 1, wherein the DTPA-mannosyl-dextran containing a molar ratio range of about 2:1 to 12:1 conjugated mannose groups to DTPA-dextran.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Farmers Insurance
Daiichi Sankyo
Mallinckrodt
Cipla
Citi
Queensland Health
Express Scripts
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.